Bristol-Myers Squibb and BioNTech announced a major deal worth up to $11 billion in early June. Click here to find out why I ...

BMS will co-develop and co-commercialize BioNTech’s bispecific antibody BNT327 for solid tumors in a deal worth up to $11.1B ...

Bristol Myers Squibb BMY recently announced a strategic collaboration agreement with BioNTech BNTX for the global ...

BioNTech SE and BMS have partnered for the global co-development and co-commercialization of BNT327 across numerous solid ...

Shares of BionNTech SE (BNTX) jumped 13% in Monday’s pre-market after the company announced that it has entered into an ...

Bristol Myers Squibb partners with BioNTech in a $11.1B deal to develop BNT327, a promising cancer immunotherapy. Read more ...

Bristol Myers Squibb and BioNTech to co-develop cancer immunotherapy BNT327 in a deal worth up to $11.1 billion.

Princeton: BioNTech SE and Bristol Myers Squibb have announced that the companies have entered into an agreement for the ...

BioNTech SE (NASDAQ:BNTX) and Bristol Myers Squibb & Co. (NYSE:BMY) entered into a co-development and co-commercialization ...

Bristol Myers Squibb (BMS) is joining forces with BioNTech in a deal that could surpass $11bn as the two drugmakers look to ...

BioNTech (NASDAQ:BNTX) surged 20% after Bristol Myers Squibb agreed to license its bispecific antibody BNT327targeting PD-L1 ...

Bristol Myers Squibb just agreed to shower BioNTech with cash. BioNTech ( BNTX 20.01%), one of the companies made famous for ...